Squaremind

Market position

SquareMind presents itself as the developer of the first robot for full-body dermoscopy, operating in the skin-screening and dermatology imaging market alongside total-body photography and remote imaging providers. Its investor base includes Sonder Capital, Bpifrance/Deeptech 2030 Fund, Adamed Technology, Calm/Storm Ventures and Teampact Ventures. Company statements describe skin screening as the highest-volume procedure in dermatology, with demand outpacing clinician capacity as populations age.

According to SquareMind, existing automated skin imaging tools such as Canfield Scientific's VECTRA WB360, MoleSafe's total-body photography system and 3Derm's remote imaging platform each address parts of the workflow, but none combine full-body dermoscopic resolution with robotic automation as Swan does. The company also contrasts Swan with the handheld dermatoscope, which remains the manual standard of care. Company materials describe Swan as the world's first robot for full-body dermoscopy.

Technology

Swan combines a robotic arm that moves around a standing patient to capture standardized dermoscopic images of the entire skin surface with AI-based review software that processes the images, tracks new or changing moles over time and flags potential risks for clinician review. The exam is contactless, guided by visual and audio prompts, and takes minutes. The company describes the output as full-body imaging at dermoscopic resolution, comparable to close-up examination of individual moles, and says the software integrates into existing clinical workflows while leaving diagnosis to the physician.

Go-to-market

SquareMind sells to dermatology practices and hospitals and said in April 2026 that it would use new funding to expand commercial, engineering and customer support teams ahead of a near-term rollout of Swan in the United States and Europe. Regulatory status in both markets - FDA listing and CE marking - is presented as the basis for commercial sale. The CEO has cited traction from practices and hospitals as a driver of the launch timing.

Dermatology practices and hospitals performing skin screening exams, and the dermatologists within them; patients are the end subjects of the exam.

Geography

Headquartered in Paris, France (address listed as 15 Rue Yves Toudic, 75010 Paris, Île-de-France). Regulatory clearances cover both the United States (FDA-listed) and Europe (CE mark), and the company is preparing commercial launches in both regions.

History

The company was founded in 2019 in Paris by Ali Khachlouf and Tanguy Serrat, and a French startup directory notes it was launched in 2019 with support from the Entrepreneur First Fund; a Bodacc filing records a share capital increase in April 2021. Over subsequent years the company developed Swan, a robotic full-body dermoscopy platform, obtained FDA listing in the United States and CE marking in Europe, and raised pre-Series A financing that was not disclosed at the time. In April 2026 SquareMind announced a total of $18 million in funding, including that earlier undisclosed financing, led by Sonder Capital, and said it was preparing a near-term commercial launch in the US and Europe.

Risks & controversies

No controversies are reported in the sources. Notable execution risks implied by the material include the fact that the company was still preparing a commercial launch as of April 2026, with no disclosed revenue or installed base, and that Swan's US regulatory pathway is described as Class I 510(k)-exempt FDA listing rather than a clearance based on clinical review. Final diagnostic responsibility remains with the physician, and the company competes against established imaging providers and the incumbent handheld dermatoscope.